Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
Candel Therapeutics (CADL) presented data at ASTRO 2026 showing aglatimagene besadenovec significantly increased immune response in prostate cancer patients over two years. The phase 3 trial showed 80% of aglatimagene patients had negative biopsies vs. 63% of controls. The company plans to submit a BLA based on these results.
How this was made
The 30-second read
Why it matters
The new biomarker data provide mechanistic validation of aglatimagene's immune‑remodeling claim, supporting the previously reported disease‑free survival benefit and may accelerate BLA filing.
Market read
First public release of supportive phase‑3 biomarker data; likely to generate short‑term upside for CADL and influence peer biotech valuations.
What to watch
Regulatory timeline for BLA submission and potential competition from other viral immunotherapies.
Background
Candel Therapeutics (NASDAQ: CADL) is a clinical‑stage biotech developing aglatimagene, an off‑the‑shelf adenoviral immunotherapy. The company has Fast Track designations for prostate, NSCLC, and pancreatic indications.
Ticker impact
Candel Therapeutics presented new phase‑3 biomarker data showing sustained immune remodeling two years after aglatimagene treatment, a first‑time disclosure.
upward pressure as market prices in the favorable immune‑remodeling results
First public release of supportive phase‑3 data; FDA Fast Track already granted, so new efficacy evidence is material and likely to improve valuation.
Market effects
Strengthens the adenovirus‑based immunotherapy niche and may boost peer biotech sentiment.
US biotech sector could see modest gains as investors reassess similar candidates.
Limited to biotech investors; no broad market effect.
Counterpoint
Data are biomarker‑focused and not direct survival outcomes; market may already price optimism.
Key entities
- companyCandel Therapeutics
Clinical‑stage biotech developing aglatimagene immunotherapy.
- productAglatimagene besadenovec
Investigational adenovirus‑based immunotherapy for localized prostate cancer.
